Please enable JavaScript to continue using this application.

Compare $ACRV vs $PTHS | Chartloom

Compare

$ACRV vs $PTHS

Acrivon Therapeutics Inc · Pelthos Therapeutics Inc

ACRV

Acrivon Therapeutics Inc

PTHS

Pelthos Therapeutics Inc

Compare $ACRV vs $PTHS

Comparing Acrivon Therapeutics Inc and Pelthos Therapeutics Inc

ACRVAcrivon Therapeutics Inc

PTHSPelthos Therapeutics Inc

ACRVAcrivon Therapeutics Inc

Market cap

$82M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-22.4%

52W performance

1.6%

FCF yield

-78.5%

PTHSPelthos Therapeutics Inc

Market cap

$71M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

0.83x

Rev growth (TTM)

—

YTD performance

-30.4%

52W performance

-27.4%

FCF yield

-70.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ACRV

PTHS

Detailed metrics comparison

ACRV

Acrivon Therapeutics Inc

PTHS

Pelthos Therapeutics Inc

Market Cap

ACRV$82M

PTHS$71M

Enterprise Value

ACRV$40M

PTHS$71M

Price

ACRV$1.91

PTHS$20.50

P/E Ratio

ACRVN/A

PTHSN/A

P/S Ratio

ACRV0.00x

PTHS1.65x

EV/Sales

ACRV0.00x

PTHS1.65x

EV/EBITDA

ACRV0.00x

PTHS0.00x

P/B Ratio

ACRV0.98x

PTHS2.03x

P/FCF Ratio

ACRVN/A

PTHSN/A

EV/FCF

ACRV-0.63x

PTHS-1.41x

PEG Ratio

ACRVN/A

PTHSN/A

Forward P/E (NTM)

ACRVN/A

PTHSN/A

Forward P/S (NTM)

ACRVN/A

PTHS0.83x

Revenue (TTM)

ACRV$0

PTHS$43M

Revenue Growth (YoY)

ACRVN/A

PTHSN/A

Forward Rev Growth

ACRV406.9%

PTHS76.2%

Gross Margin (TTM)

ACRV0.0%

PTHS78.6%

Operating Margin (TTM)

ACRV0.0%

PTHS0.0%

EBITDA Margin (TTM)

ACRV0.0%

PTHS-121.6%

Net Margin (TTM)

ACRV0.0%

PTHS-165.2%

FCF Margin (TTM)

ACRVN/A

PTHS-116.6%

Net Income (TTM)

ACRV$-74M

PTHS$-72M

FCF (TTM)

ACRV$-64M

PTHS$-50M

EPS (TTM)

ACRV-$1.77

PTHS-$20.22

ROE (TTM)

ACRV-7014.0%

PTHS-7804.0%

ROA (TTM)

ACRV-6161.0%

PTHS-6701.0%

ROIC (TTM)

ACRV-7014.0%

PTHS-5896.0%

Cash

ACRV$41M

PTHS$0

Debt

ACRV$0

PTHS$0

Net Cash/Debt

ACRV$41M

PTHS$0

Current Ratio (TTM)

ACRV7.99x

PTHS2.05x

Quick Ratio (TTM)

ACRV7.86x

PTHS1.10x

Debt/Equity (TTM)

ACRV0.00x

PTHS0.81x

Debt/Assets (TTM)

ACRV0.0%

PTHS0.0%

Interest Coverage (TTM)

ACRVN/A

PTHSN/A

Net Debt/EBITDA (TTM)

ACRV0.00x

PTHS0.00x

Beta

ACRV1.95

PTHS3.13

52W Performance

ACRV1.6%

PTHS-27.4%

YTD Performance

ACRV-22.4%

PTHS-30.4%

% from 52W High

ACRV-46.3%

PTHS-45.3%

% from 52W Low

ACRV50.4%

PTHS12.7%

Asset Turnover (TTM)

ACRV0.00x

PTHS0.00x

FCF Yield (TTM)

ACRV-78.5%

PTHS-70.8%

Earnings Yield (TTM)

ACRV-90.8%

PTHS-100.3%

Dividend Yield (TTM)

ACRVN/A

PTHSN/A

Rule of 40

ACRV0.0

PTHS-116.6

EV/GP/RG

ACRVN/A

PTHS0.02

Ticker research

View ACRV research View PTHS research

Metric	ACRV Acrivon Therapeutics Inc	PTHS Pelthos Therapeutics Inc
Market & Valuation
Market Cap	$82M	$71M
Enterprise Value	$40M	$71M
Price	$1.91	$20.50
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	1.65x
EV/Sales	0.00x	1.65x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.98x	2.03x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.63x	-1.41x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.83x
Revenue & Growth
Revenue (TTM)	$0	$43M
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	406.9%	76.2%
Profitability
Gross Margin (TTM)	0.0%	78.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-121.6%
Net Margin (TTM)	0.0%	-165.2%
FCF Margin (TTM)	N/A	-116.6%
Net Income (TTM)	$-74M	$-72M
FCF (TTM)	$-64M	$-50M
EPS (TTM)	-$1.77	-$20.22
ROE (TTM)	-7014.0%	-7804.0%
ROA (TTM)	-6161.0%	-6701.0%
ROIC (TTM)	-7014.0%	-5896.0%
Financial Health
Cash	$41M	$0
Debt	$0	$0
Net Cash/Debt	$41M	$0
Current Ratio (TTM)	7.99x	2.05x
Quick Ratio (TTM)	7.86x	1.10x
Debt/Equity (TTM)	0.00x	0.81x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.95	3.13
52W Performance	1.6%	-27.4%
YTD Performance	-22.4%	-30.4%
% from 52W High	-46.3%	-45.3%
% from 52W Low	50.4%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-78.5%	-70.8%
Earnings Yield (TTM)	-90.8%	-100.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-116.6
EV/GP/RG	N/A	0.02
Ticker research	View ACRV research	View PTHS research

Valuation

P/S Ratio

ACRV

0.00x

PTHS

1.65x

EV/FCF

PTHS

-1.41x

ACRV

-0.63x

Growth & revenue

Forward Revenue Growth

ACRV

406.9%

PTHS

76.2%

Profitability & performance

Gross Margin

PTHS

78.6%

ACRV

0.0%

ROE

ACRV

-7014.0%

PTHS

-7804.0%

FCF Yield %

PTHS

-70.8%

ACRV

-78.5%

52-Week Performance

ACRV

1.6%

PTHS

-27.4%

Detailed metrics comparison

ACRV

Acrivon Therapeutics Inc

PTHS

Pelthos Therapeutics Inc

Market Cap

ACRV$82M

PTHS$71M

Enterprise Value

ACRV$40M

PTHS$71M

Price

ACRV$1.91

PTHS$20.50

P/E Ratio

ACRVN/A

PTHSN/A

P/S Ratio

ACRV0.00x

PTHS1.65x

EV/Sales

ACRV0.00x

PTHS1.65x

EV/EBITDA

ACRV0.00x

PTHS0.00x

P/B Ratio

ACRV0.98x

PTHS2.03x

P/FCF Ratio

ACRVN/A

PTHSN/A

EV/FCF

ACRV-0.63x

PTHS-1.41x

PEG Ratio

ACRVN/A

PTHSN/A

Forward P/E (NTM)

ACRVN/A

PTHSN/A

Forward P/S (NTM)

ACRVN/A

PTHS0.83x

Revenue (TTM)

ACRV$0

PTHS$43M

Revenue Growth (YoY)

ACRVN/A

PTHSN/A

Forward Rev Growth

ACRV406.9%

PTHS76.2%

Gross Margin (TTM)

ACRV0.0%

PTHS78.6%

Operating Margin (TTM)

ACRV0.0%

PTHS0.0%

EBITDA Margin (TTM)

ACRV0.0%

PTHS-121.6%

Net Margin (TTM)

ACRV0.0%

PTHS-165.2%

FCF Margin (TTM)

ACRVN/A

PTHS-116.6%

Net Income (TTM)

ACRV$-74M

PTHS$-72M

FCF (TTM)

ACRV$-64M

PTHS$-50M

EPS (TTM)

ACRV-$1.77

PTHS-$20.22

ROE (TTM)

ACRV-7014.0%

PTHS-7804.0%

ROA (TTM)

ACRV-6161.0%

PTHS-6701.0%

ROIC (TTM)

ACRV-7014.0%

PTHS-5896.0%

Cash

ACRV$41M

PTHS$0

Debt

ACRV$0

PTHS$0

Net Cash/Debt

ACRV$41M

PTHS$0

Current Ratio (TTM)

ACRV7.99x

PTHS2.05x

Quick Ratio (TTM)

ACRV7.86x

PTHS1.10x

Debt/Equity (TTM)

ACRV0.00x

PTHS0.81x

Debt/Assets (TTM)

ACRV0.0%

PTHS0.0%

Interest Coverage (TTM)

ACRVN/A

PTHSN/A

Net Debt/EBITDA (TTM)

ACRV0.00x

PTHS0.00x

Beta

ACRV1.95

PTHS3.13

52W Performance

ACRV1.6%

PTHS-27.4%

YTD Performance

ACRV-22.4%

PTHS-30.4%

% from 52W High

ACRV-46.3%

PTHS-45.3%

% from 52W Low

ACRV50.4%

PTHS12.7%

Asset Turnover (TTM)

ACRV0.00x

PTHS0.00x

FCF Yield (TTM)

ACRV-78.5%

PTHS-70.8%

Earnings Yield (TTM)

ACRV-90.8%

PTHS-100.3%

Dividend Yield (TTM)

ACRVN/A

PTHSN/A

Rule of 40

ACRV0.0

PTHS-116.6

EV/GP/RG

ACRVN/A

PTHS0.02

Ticker research

View ACRV research View PTHS research

Metric	ACRV Acrivon Therapeutics Inc	PTHS Pelthos Therapeutics Inc
Market & Valuation
Market Cap	$82M	$71M
Enterprise Value	$40M	$71M
Price	$1.91	$20.50
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	1.65x
EV/Sales	0.00x	1.65x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.98x	2.03x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.63x	-1.41x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.83x
Revenue & Growth
Revenue (TTM)	$0	$43M
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	406.9%	76.2%
Profitability
Gross Margin (TTM)	0.0%	78.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-121.6%
Net Margin (TTM)	0.0%	-165.2%
FCF Margin (TTM)	N/A	-116.6%
Net Income (TTM)	$-74M	$-72M
FCF (TTM)	$-64M	$-50M
EPS (TTM)	-$1.77	-$20.22
ROE (TTM)	-7014.0%	-7804.0%
ROA (TTM)	-6161.0%	-6701.0%
ROIC (TTM)	-7014.0%	-5896.0%
Financial Health
Cash	$41M	$0
Debt	$0	$0
Net Cash/Debt	$41M	$0
Current Ratio (TTM)	7.99x	2.05x
Quick Ratio (TTM)	7.86x	1.10x
Debt/Equity (TTM)	0.00x	0.81x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.95	3.13
52W Performance	1.6%	-27.4%
YTD Performance	-22.4%	-30.4%
% from 52W High	-46.3%	-45.3%
% from 52W Low	50.4%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-78.5%	-70.8%
Earnings Yield (TTM)	-90.8%	-100.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-116.6
EV/GP/RG	N/A	0.02
Ticker research	View ACRV research	View PTHS research